From the Guidelines
For women with generalized anxiety disorder (GAD) and panic disorder who cannot tolerate SSRIs due to TIA-like symptoms, the most effective treatment option is to use SNRIs such as venlafaxine (75-225mg daily) or duloxetine (30-60mg daily), as they may be tolerated better than SSRIs, according to the study by 1. This is because SNRIs affect both serotonin and norepinephrine, which can help modulate the stress response and reduce anxiety symptoms. Other alternative treatment options include:
- Benzodiazepines like lorazepam (0.5-2mg twice daily), clonazepam (0.25-1mg twice daily), or alprazolam (0.25-0.5mg three times daily) for short-term use (2-4 weeks) due to dependence risks.
- Buspirone (7.5-15mg twice daily) for GAD with minimal side effects and no dependence issues.
- Pregabalin (150-600mg daily in divided doses) or gabapentin (300-900mg three times daily) for anxiety with fewer cardiovascular concerns.
- Hydroxyzine (25-50mg three to four times daily) for non-addictive anxiolytic effects. It is also recommended to incorporate cognitive behavioral therapy (CBT) as a first-line treatment, typically involving 12-16 weekly sessions, as suggested by 1 and 1. A combination approach using both medication and psychotherapy typically yields the best outcomes. The choice of medication should be governed by considerations such as pharmacokinetics, pharmacodynamics, tolerability, cost, insurance formularies, and unique risks leading to warnings or precautions, as mentioned in 1.
From the FDA Drug Label
Buspirone hydrochloride tablets are indicated for the management of anxiety disorder or the short-term relief of the symptoms of anxiety. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD).
For a woman who cannot tolerate SSRIs due to TIA like symptoms, buspirone may be a suitable treatment option for GAD.
- Buspirone has been shown to be effective in managing anxiety disorder and relieving symptoms of anxiety in patients with GAD.
- It is also effective in patients with coexisting depressive symptoms. However, its effectiveness in treating panic disorder is not directly addressed in the provided drug label 2. Therefore, no conclusion can be drawn regarding the use of buspirone for panic disorder.
From the Research
Treatment Options for GAD and Panic Disorder
For women who cannot tolerate SSRIs due to TIA-like symptoms, several alternative treatment options are available:
- Pregabalin, an anxiolytic agent, has been approved for the treatment of generalized anxiety disorder (GAD) in adults 3.
- Cognitive-behavioral therapy (CBT) is considered a first-line treatment for GAD and panic disorder, with various approaches showing similar effectiveness 4, 5.
- Other antidepressants, such as serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors, can be considered as alternatives to SSRIs 6.
- Relaxation therapy and third-wave cognitive behavior therapies may also be effective in reducing GAD symptoms 5.
- Buspirone, beta blockers, and hydroxyzine can be considered as third-line agents for panic disorder 6.
Medication Considerations
When considering medication, it is essential to weigh the potential benefits and risks:
- Pregabalin has a distinct mechanism of action and a relatively low risk of abuse and withdrawal symptoms 3.
- Benzodiazepines can be effective in reducing anxiety symptoms but are limited by their risk of abuse and adverse effect profiles 7.
- Anticonvulsants and antipsychotics may be helpful, but the evidence base is limited 6.
Psychotherapy Considerations
Psychotherapy can be an effective treatment for GAD and panic disorder:
- CBT has an extensive evidence base and is considered a first-line treatment for GAD and panic disorder 4, 5, 7.
- Relaxation therapy and third-wave cognitive behavior therapies may also be effective in reducing GAD symptoms 5.
- The choice of psychotherapy should be tailored to the individual patient's needs and preferences.